Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.

Novo Nordisk sells semaglutide under the brands Wegovy and Ozempic for weight loss and type 2 diabetes treatment respectively. Image credit: Getty/UCG. A US judge has rejected efforts by a compounded ...

Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.

Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.

Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.

Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid ...

The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders.

Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

Nordic biopharma innovation outpaces commercialization as regional biotechs struggle to raise the capital needed to upscale.

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.

WuXi XDC Cayman is to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 platform to develop an ADC candidate.

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.